Evaluating Safety and Effects of HRS9531 Injection Compared to Placebo in Adolescents Aged 12 to 18 with Obesity

What this Trial Is About

This research aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS9531 injection compared with placebo in adolescents aged 12 to 18 years with obesity. The study focuses on understanding how the drug behaves in the body and its effects in this specific age group, addressing important safety and treatment questions under medical supervision. Participants are randomly assigned to one of three treatment groups receiving low, medium, or high doses of HRS9531 injection or placebo. The study is double-blinded, meaning neither participants nor researchers know who receives the drug or placebo. The treatment period lasts up to 28 weeks during which various doses are assessed for their effects. During the trial, participants will have assessments including monitoring for adverse events, measuring drug concentration levels, and evaluating changes in body mass index, body weight, and waist circumference. Antibody responses to the drug will also be tracked. Safety and tolerability are closely observed throughout the study, and participation lasts through the treatment and follow-up up to week 28.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity